Affibody AB

Lonza

Xbrane enters licensing agreement with Indian generics giant

Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.

The top five most expensive drugs in 2025

New advanced therapeutic medicines are reaching the market, but their price tags remain exceptionally high. This year’s ranking of the most expensive drugs in t...

Emerson

Planerar ni en klinisk studie? Tänk på det här.

Att genomföra en klinisk studie är en komplex och resurskrävande process som kräver noggrann planering och riskhantering. För företag inom life science-sektorn ...

Large study on milk: Risky for women but not for men

The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while n...

Hypothesis testing versus conspiracy theory

"How do you know what is a conspiracy theory and what is a reasonable, scientifically based conclusion?" In a column, Ingrid Lönnstedt reflects on this question.

Nanexa finalist i Fierce Innovation Awards

Uppsalabolaget Nanexa har utsetts till finalist i den internationella tävlingen Fierce Innovation Awards Life Sciences. Bolaget uppmärksammas i kategorin Drug D...

Wusson Accelerator AB

Därför är det viktigt att förbereda ångsystemet i god tid

Även om sommaren närmar sig sitt slut finns det fortfarande tid att optimera ditt ångsystem. Små justeringar nu kan resultera i betydande energibesparingar och ...

Festo liquid dispensing: going fast and slow

Dispensing liquid with Festo equipment developed for automation can really be adapted to your needs

ZEISS Insights: Measurement of bone plates and screws

Get free access to technical paper.

Optimize Courier SUPPLIERS (DISTRIBUTORS)

Novo Nordisk to invest billions in new quality control lab

Novo Nordisk has announced plans to invest 2.9 billion Danish kroner in order to establish a new quality control laboratory in Hillerød in northern Zealand, Denmark.

ZEISS Connected Quality: One metrology hub

The new product family ZEISS CONNECTED QUALITY is the solution for quick and secure data exchange, quality management and efficient system monitoring.

600 million SEK for life science - "Should not be the country of moderation"

Sweden will prioritize excellence over breadth in research. This was made clear when the government presented the research proposition for the next four years.

New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require...

”Lös problemen i journalsystemet Take Care”

Ett sjukhus eller region fungerar idag som ett stort nätverk av tjänster och behöver därför öka analysförmågan av hela det tekniska nätverket för att förkorta a...

Grönt ljus för diabetespiller för att reducera hjärtrisker

FDA godkänner Novo Nordisks Rybelsus för behandling av allvarliga hjärt-kärlhändelser hos vuxna med typ 2-diabetes. Det är första gången ett oralt GLP-1-läkemed...

”Sverige riskerar tappa forskartalanger – dags att bygga broar”

Debatten om arbetskraftsinvandring är het i Sverige. Men när vi diskuterar kvoter och restriktioner missar vi en avgörande aspekt: Vad händer med de internation...

Fast Optical Sectioning of Developing Organisms and Tissue Microstructures

ZEISS Lattice SIM 3 exploits the full potential of the SIM Apotome technology.

Novo Nordisk establishes new factory in Denmark

Novo Nordisk establishes a new production facility in Odense, Denmark, an investment of 8.5 billion Danish kroner.

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."